antibacterial toxin-derived immunotoxins: innovative constructs for targeted breast cancer treatment

Cancer remains one of humanity’s leading causes of both illness and death globally. in women worldwide, breast cancer remains the most widespread malignant condition. the new possibilities for direct treatment offered by the advances made thereby were the subject of the recent study undertaken as it sought to unravel tumorigenesis through genetics and molecular appreciation of cancer. specifically, this research centers on devising and testing immunotoxins as anti-bacterial toxin-based constructs to treat breast cancer. these immunotoxins can kill cancer cells selectively while leaving normal tissues unharmed as they bind only to cancer cell antigens by using both the specificity of antibodies and bacterial toxins’ cytotoxicity power. we assessed immunotoxins’ binding affinities to their respective antigens based on computational dockings like haddock explaining encouraging results characterized by good docking scores accompanied by low rmsds—also, dual targeting approaches combined with structure-based. by developing humanized antibodies and novel targeting moieties, challenges such as immunogenicity and non-specific toxicity have been tackled. our findings suggest that optimized immunotoxins have great potential to enhance therapeutic window as well as efficacy in cancer treatments